Simantini Eddy

611 total citations
8 papers, 409 citations indexed

About

Simantini Eddy is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Simantini Eddy has authored 8 papers receiving a total of 409 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Simantini Eddy's work include Cancer Immunotherapy and Biomarkers (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). Simantini Eddy is often cited by papers focused on Cancer Immunotherapy and Biomarkers (3 papers), Pancreatic and Hepatic Oncology Research (2 papers) and Renal cell carcinoma treatment (2 papers). Simantini Eddy collaborates with scholars based in United States, Switzerland and Singapore. Simantini Eddy's co-authors include Mark N. Stein, Robert S. DiPaola, Susan Goodin, Hongxia Lin, Chandrika Jeyamohan, Eileen White, Murugesan Gounder, Dmitri Dvorzhinski, Kevin Bray and Diane Healey and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and BMC Cancer.

In The Last Decade

Simantini Eddy

8 papers receiving 403 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Simantini Eddy United States	6	190	165	161	97	76	8	409
Αναστασία Κοττόρου Greece	15	245 1.3×	172 1.0×	175 1.1×	71 0.7×	91 1.2×	37	510
Rujun Mo China	13	282 1.5×	115 0.7×	147 0.9×	120 1.2×	67 0.9×	21	454
Min Peng China	14	213 1.1×	206 1.2×	136 0.8×	137 1.4×	72 0.9×	60	521
Juan Ramón Delgado Spain	12	219 1.2×	151 0.9×	103 0.6×	73 0.8×	54 0.7×	24	416
Antonino Belfiore Italy	12	211 1.1×	157 1.0×	156 1.0×	88 0.9×	30 0.4×	20	473
Noga Bloushtain-Qimron United States	7	258 1.4×	137 0.8×	130 0.8×	49 0.5×	52 0.7×	8	375
Zhuqing Zhou China	14	329 1.7×	150 0.9×	205 1.3×	97 1.0×	66 0.9×	26	529
Julian Musa Germany	8	334 1.8×	113 0.7×	136 0.8×	108 1.1×	39 0.5×	18	500
Shao‐Lan Qin China	13	269 1.4×	179 1.1×	140 0.9×	53 0.5×	93 1.2×	26	482
Kazunoshin Tachibana Japan	10	189 1.0×	208 1.3×	124 0.8×	92 0.9×	170 2.2×	33	470

Countries citing papers authored by Simantini Eddy

Since Specialization

Citations

This map shows the geographic impact of Simantini Eddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simantini Eddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simantini Eddy more than expected).

Fields of papers citing papers by Simantini Eddy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simantini Eddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simantini Eddy. The network helps show where Simantini Eddy may publish in the future.

Co-authorship network of co-authors of Simantini Eddy

This figure shows the co-authorship network connecting the top 25 collaborators of Simantini Eddy. A scholar is included among the top collaborators of Simantini Eddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simantini Eddy. Simantini Eddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Santoro, Armando, Daniel Shao-Weng Tan, Jon Zugazagoitia, et al.. (2024). Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC. BMC Cancer. 24(1). 1307–1307. 2 indexed citations

Cheung, Wing K., et al.. (2015). Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers. Clinical Pharmacology Advances and Applications. 7. 11–11. 9 indexed citations

Stein, Mark N., Susan Goodin, Susan Doyle-Lindrud, et al.. (2012). Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Medical Science Monitor. 18(4). CR260–CR264. 14 indexed citations

Moss, Rebecca A., Mary F. Mulcahy, Kenneth Nahum, et al.. (2012). A Multi-institutional Phase 2 Study of Imatinib Mesylate and Gemcitabine for First-Line Treatment of Advanced Pancreatic Cancer.. PubMed. 5(3). 77–83. 18 indexed citations

Stein, Mark N., Maha Hussain, Edwin M. Posadas, et al.. (2011). Phase II study of AT-101 to abrogate Bcl-2-mediated resistance to androgen-deprivation therapy (ADT) in patients (pts) with newly diagnosed androgen-dependent metastatic prostate cancer (ADMPC).. Journal of Clinical Oncology. 29(7_suppl). 137–137. 3 indexed citations

Stein, Mark N., Hongxia Lin, Chandrika Jeyamohan, et al.. (2010). Targeting tumor metabolism with 2‐deoxyglucose in patients with castrate‐resistant prostate cancer and advanced malignancies. The Prostate. 70(13). 1388–1394. 238 indexed citations

Rini, Brian I., Mark N. Stein, Simantini Eddy, et al.. (2010). Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 117(4). 758–767. 119 indexed citations

Gordon, Michael, Mark N. Stein, Simantini Eddy, et al.. (2009). Phase I dose escalation trial of tremelimumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology. 27(15_suppl). 5115–5115. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact